Most Recent
Construction PRO
Lendlease scores pharma giant as latest Victoria Cross Tower tenant
Construction 2025-08-22 11:09 pm By Julia Kanapathippillai

Global pharmaceutical company Novartis has become the latest tenant at Lendlease’s Victoria Cross Tower in North Sydney. Novartis ANZ will set up shop across one floor of the building, occupying 1,700 square metres in the mid-rise of the building, Lendlease said Thursday. The skyscraper is more than 30 per cent leased, with 70 percent of…

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Bayer can’t get High Court to hear Xarelto patent fight
Intellectual Property 2025-03-07 11:10 pm By Christine Caulfield

The High Court won’t hear Bayer’s appeal of an invalidity finding over patents for blood thinner Xarelto, despite the company’s claim the decision has “profound” consequences for drug R&D.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Lundbeck, Sandoz end long-running Lexapro patent war
Intellectual Property 2025-02-27 11:06 pm By Christine Caulfield

Pharmaceutical giant Lundbeck has resolved its battle with Novartis unit Sandoz over top-selling drug Lexapro, a battle that has raged for years and across multiple courts.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Novartis appeals IP win for Pharmacor over blood pressure drug
Appeals 2025-01-20 11:42 pm By Christine Caulfield

Pharmaceutical giant Novartis is challenging the loss of its case against Sydney-based generics company Pharmacor over a patent for heart medication Entresto.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Novartis can’t appeal loss of experts in MS drug patent feud with Pharmacor
Intellectual Property 2022-04-07 12:29 pm By Christine Caulfield

The Full Federal Court won’t give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Full Court deals drug companies a blow on patent term extensions
Intellectual Property 2022-03-18 10:27 pm By Miklos Bolza

The Full Court has upheld two judgments that shortened patent term extensions granted to Merck Sharpe & Dohme and Ono Pharmaceuticals, finding the extension regime cannot be construed as achieving a “commercial outcome for a patentee”.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Judge tosses Novartis experts out of ‘hot tub’ in MS drug patent dispute
Intellectual Property 2022-03-18 5:54 pm By Miklos Bolza

A judge has slammed Novartis for putting forward four “overlapping” experts in a dispute with Pharmacor over patents for its MS drug Gilenya and thrown three of those experts out of an upcoming joint conferral, known as a “hot tub”.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

High Court finds Sandoz infringed Lundbeck’s Lexapro patent
High Court 2022-03-09 4:40 pm By Miklos Bolza

The High Court has found that Novartis unit Sandoz infringed Danish drug company Lundbeck’s patent for its blockbuster antidepressant Lexapro, but has overturned a ruling that found the generic drug maker owes $26.3 million in damages.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Biogen may sue third generic drug maker to protect MS drug Tecfidera
Intellectual Property 2021-12-10 4:14 pm By Cat Fredenburgh

Swiss pharmaceutical company Biogen is considering a third patent infringement lawsuit against a drug maker to shield its monopoly in Australia for blockbuster multiple sclerosis drug Tecfidera from generic competition.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Court throws out Merck Sharp & Dohme’s Januvia patent extension
Intellectual Property 2021-08-12 2:29 pm By Miklos Bolza

The Federal Court has dealt US drug giant Merck Sharp & Dohme a devastating blow, overturning an “untenable” patent term extension which would have protected the monopoly of its multibillion-dollar Januvia and Janumet diabetes drugs beyond July 2o22.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?